Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bacillus coagulans MTCC 5856 and Reduced Abdominal Pain

Research synthesisModerate evidenceLarge effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across all 3 studies, Bacillus coagulans MTCC 5856 consistently shows beneficial effects on reducing abdominal pain, with predominantly large effect sizes. The evidence includes a large systematic review (n=9253) and two smaller randomized controlled trials in adults with IBS or functional gas and bloating. The most studied dose is approximately 2 × 10^9 CFU/day (2 billion spores/day), and effects are observed in clinical populations with IBS or functional bloating.

  • Effective dose range: 2 × 10^9 CFU/day (2 billion spores/day)
  • Studied populations: adults with IBS, adults with diarrhea-predominant IBS, adults with functional gas and bloating

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Study durations were not consistently reported, and one trial (n=36) had a very small sample size.

Generated Jun 12, 2026
Doses used in studies
  • CFU/day: 2 billion (median 2 billion, IQR 2 billion2 billion) 1 study
  • spores/day: 2 billion (median 2 billion, IQR 2 billion2 billion) 1 study
Safety in these studies
3 of 3 papers
Back to top